Data from longest reported follow-up for a Phase 3 trial with immunotherapy in metastatic non-small cell lung cancer demonstrate consistent, durable benefits of Opdivo plus Yervoy vs. This trial is slightly different, it only gives 2 cycles of chemotherapy up front, whereas the POSEIDON study NCT03164616 gives the standard 4 cycles of chemotherapy. In 2021, the CheckMate 9LA Phase 3 trial, stratified patients by PD-L1 1 and <1, showed that nivolumab in combination with ipilimumab plus two cycles of.
0 kommentar(er)
